COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C) Risk / World Health Organization (WHO) (REPI)

SARS-COV-2 (virus Responsible of COVID-19) Reinfection and Multisystem Inflammatory Syndrome in Children (MIS-C) Risk: Matched Case-control Study

This study is a multicenter, international, non interventional, retrospective study about SARS-CoV-2 and Multisystem Inflammatory Syndrome (MIS-C) reinfection risk in children.

Study Overview

Status

Completed

Detailed Description

This study is based to data collection of cases (patients with MIS-C) compare to controls (patients with SARS-CoV-2 infection) occurring between 01 sep 2021 and 30 apr 2022. For this study cases and controls group will be matched for analyses.

The main of this study is to evaluate the difference of risk of occurrence of MIS-C between a first SARS-CoV-2 infection and a reinfection with SARS-CoV-2.

Study Type

Observational

Enrollment (Actual)

204

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Créteil, France, 94000
        • ACTIV

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

children with SARS-CoV-2 and children with MIS-C between the 01 sep 2021 and 30 apr 2022 period

Description

Inclusion Criteria:

group 1: cases

  • Patients with MIS-C (following SARS CoV-2 infection)
  • Hospitalised between the 01 sep 2021 and 30 apr 2022
  • Under 18 years of age
  • Not vaccinated for SARS-CoV-2

group 2: controls

  • Patients not hospitalised, treated by outpatient care
  • With documented SARS-CoV-2 infection between the 01 sep 2021 and 30 apr 2022
  • Matched with a case on age (+/- 6 months), gender and country
  • Not vaccinated for SARS-CoV-2

Exclusion Criteria:

- Refusal to participate by patient relative or legal representative

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
children with MIS-C
hospitalized children with MIS-C
SARS-CoV-2 infection
non hospitalized children infected with SARS-CoV-2 treated by outpatient care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
proportion of MIS-C cases occurred after first SARS-CoV-2 infection
Time Frame: 8 months
Assessment of risk of MIS-C after first SARS-CoV-2 infection
8 months
proportion of MIS-C cases occurred after SARS-CoV-2 reinfection
Time Frame: 8 months
Assessment of risk of MIS-C after SARS-CoV-2 reinfection
8 months
Proportion of SARS-CoV-2 reinfection after first SARS-CoV-2 infection
Time Frame: 8 months
Assessment of risk of SARS-CoV-2 reinfection after first SARS-CoV-2 infection
8 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Corinne Levy, Physician, Association Clinique Thérapeutique Infantile du val de Marne
  • Principal Investigator: Naim Ouldali, Physician, Hôpital Robert Debré AP-HP, Paris 19

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 22, 2023

Primary Completion (Actual)

April 1, 2024

Study Completion (Actual)

April 1, 2024

Study Registration Dates

First Submitted

February 7, 2024

First Submitted That Met QC Criteria

February 7, 2024

First Posted (Actual)

February 13, 2024

Study Record Updates

Last Update Posted (Estimated)

November 21, 2024

Last Update Submitted That Met QC Criteria

November 19, 2024

Last Verified

November 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe